Echo IQ Limited (ASX:EIQ) has moved into the second camp. The company’s latest announcement, a binding heads of agreement with Pro Medicus Limited, landed on 25 June 2026 and was followed by a sharp move in the share price, with StockLight showing EIQ up 25.7% to A$1.67 after the release.
That does not settle the investment debate. It changes the shape of it.
Pro Medicus Limited (ASX:PME) is not a casual name in medical software. The company describes itself as a healthcare informatics business founded in 1983, with medical imaging software and services used by hospitals, imaging centres and healthcare groups. For EchoIQ, which is trying to turn AI-based cardiac decision support into a commercial healthcare product, the significance is not just the agreement. It is the possible validation that comes from the counterparty.
The story is shifting from clearance to distribution
EchoIQ’s cleared product, EchoSolv AS, is designed as a decision-support aid for detecting severe aortic stenosis. The company received US FDA 510(k) clearance for EchoSolv AS in October 2024, allowing it to market the product to healthcare professionals in the United States.
That matters because FDA clearance can open the door, but it does not fill the waiting room.
The harder stage is adoption. Hospitals need workflow fit. Clinicians need trust. Administrators need a reason to add another layer to systems that are already crowded. EchoIQ has been trying to answer that with US deployments and partnerships rather than just technical claims.
In April, the company said EchoSolv AS had been deployed with Mount Sinai Health System in New York, a network that includes seven hospitals, more than 400 outpatient practices and more than 3,760 beds. In the March quarter, EchoIQ also reported more than 50 active US accounts and three closed-won contracts.
That is the more useful lens. The Pro Medicus announcement is not sitting by itself. It follows a sequence of commercial signals.
Mayo keeps the heart failure pathway in view
The other part of the EchoIQ story is heart failure.
EchoIQ has FDA clearance for aortic stenosis, but its heart failure indication remains under review. In a 12 June 2026 announcement, the company said its AI platform had not yet received FDA clearance or approval for heart failure, and there was no assurance clearance would be obtained on the expected timeline or at all.
That warning is not boilerplate noise. It is central to the story.
The company’s collaboration with Mayo Clinic is aimed at evaluating AI-driven cardiac risk stratification in oncology patients using echocardiographic data. The study is expected to process de-identified data and assess whether EchoIQ’s model can generate heart failure risk scores for patients undergoing cancer therapy, with completion expected in the first half of 2027.
The appeal is easy to understand. If EchoIQ can move from a single cleared use case into a broader cardiac risk platform, the addressable market becomes more interesting. The proof, though, still has to come through clinical validation, regulatory progress and paid adoption.
The market is rewarding proximity to serious healthcare infrastructure
There is a reason the share price reacted strongly.
EchoIQ is building around names that matter in US healthcare: Mount Sinai, Mayo Clinic and now Pro Medicus. That gives investors a cleaner story to follow than a typical early-stage AI pitch. The company is not only talking about algorithms. It is trying to place its software inside recognised clinical and imaging ecosystems.
That is the constructive reading.
The more cautious reading is that partnerships and heads of agreement still need to become revenue, usage and renewal behaviour. Healthcare software can take time to sell. Clinical workflows are slow to change. Reimbursement, FDA scope and evidence quality can all affect adoption.
The old story was whether EchoIQ had a product. The new story is whether enough serious institutions will use it at commercial scale.
The next filings need to show what the headlines cannot
EchoIQ has also been adding people around the commercial push. On 24 June 2026, it appointed Matthew Dodds as Chief Financial Officer and Dr Vinod Thourani as Clinical Advisor, with the company saying the appointments support US commercial growth and FDA initiatives.
That fits the moment. The company needs financial discipline, clinical credibility and US healthcare access at the same time.
From here, the market will be watching for cleaner evidence: signed commercial terms, deployment pace, recurring revenue, product usage, reimbursement progress and any FDA update on heart failure. The Pro Medicus agreement may be an important marker. It is not the finish line.
For EchoIQ, the question after 25 June 2026 is simple enough. Can the company turn recognition into routine clinical use?
